BC
ASPX

Broadfin Capital’s AUSPEX PHARMACEUTICALS INC COM STK (DE) ASPX Stock Holding History

Broadfin Capital’s Portfolio ASPX Stock Details ASPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-100,000
Closed -$5.25M – 94
2014
Q4 		$5.25M Buy
+100,000
New +$2.94M 0.46% 49

Other funds holding ASPX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Broadfin Capital's ASPX Position: Q1 2015 in Review

Broadfin Capital sold out of AUSPEX PHARMACEUTICALS INC COM STK (DE) (ASPX) in Q1 2015, closing a stake of 100,000 shares — an estimated $5.25M sold.

Broadfin Capital first reported a position in ASPX in Q4 2014 and held it in 1 quarter. The position peaked at $5.25M in Q4 2014. 138 funds tracked by Wall St. Rank hold ASPX as of Q1 2015.

  • Broadfin Capital reported no remaining AUSPEX PHARMACEUTICALS INC COM STK (DE) position as of Q1 2015 after selling out during the quarter.
  • Broadfin Capital sold 100,000 AUSPEX PHARMACEUTICALS INC COM STK (DE) shares in Q1 2015, an estimated $5.25M.
  • Broadfin Capital first reported a position in AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q4 2014 and held it in 1 quarter.
  • Broadfin Capital's AUSPEX PHARMACEUTICALS INC COM STK (DE) position peaked at $5.25M in Q4 2014.
  • 138 funds tracked by Wall St. Rank held AUSPEX PHARMACEUTICALS INC COM STK (DE) as of Q1 2015.

Based on Broadfin Capital's 13F filing for Q1 2015, filed 15 May 2015.